Table 2 5- and 10-year survival for entire cohort and by subgroup
Feature | 5-Year OS (standard error) (%) | 10-Year OS (standard error) (%) | p |
|---|---|---|---|
Overall | 92.2 (1.5) | 91.6 (1.6) | |
Gender | 0.376 | ||
Male | 91.7 (1.8) | 91.0 (1.9) | |
Female | 94.0 (2.9) | 94.0 (2.9) | |
Race | 0 | .607 | |
White | 92.4 (1.7) | 91.7 (1.8) | |
Black | 96.8 (3.2) | 96.8 (3.2) | |
Others | 84.3 (7.3) | 84.3 (7.3) | |
Age at diagnosis | 0.261 | ||
≤ 10-year-old | 94.6 (2.0) | 90.9 (3.3) | |
> 10-year-old | 90.4 (2.2) | 89.1 (2.5) | |
Primary sites | 0.041 | ||
Small bowel | 91.1 (2.4) | 91.1 (2.4) | |
Large bowel | 95.9 (1.8) | 94.5 (2.3) | |
Stomach | 81.3 (6.9) | 81.3 (6.9) | |
Tumor histology | 0.477 | ||
Burkitt | 93.1 (1.9) | 93.1 (1.9) | |
DLBCL | 93.3 (2.6) | 91.0 (3.4) | |
Others | 86.6 (5.2) | 86.6 (5.2) | |
SEER stage | 0.277 | ||
Localized | 94.9 (2.0) | 93.5 (2.4) | |
Regional | 93.1 (2.4) | 93.1 (2.4) | |
Distant | 86.3 (4.3) | 86.3 (4.3) | |
Surgery | 0.399 | ||
Yes | 93.1 (1.7) | 93.1 (1.7) | |
No | 90.1 (3.1) | 87.7 (3.8) | |
Chemotherapy | < 0.001 | ||
Yes | 94.0 (1.5) | 93.4 (1.6) | |
No | 78.4 (6.8) | 78.4 (6.8) | |
Treatment regimens | 0.001 | ||
Chemotherapy alone | 94.3 (2.8) | 91.2 (4.0) | |
Surgery alone | 80.0 (10) | 80.0 (10) | |
Chemotherapy + surgery | 94.0 (1.7) | 94.0 (1.7) |